Amalgamated Bank Purchases 2,228 Shares of Cencora, Inc. (NYSE:COR)

Amalgamated Bank lifted its holdings in Cencora, Inc. (NYSE:COR) by 6.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 37,969 shares of the company’s stock after buying an additional 2,228 shares during the quarter. Amalgamated Bank’s holdings in Cencora were worth $8,546,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of COR. Price T Rowe Associates Inc. MD bought a new stake in Cencora during the 1st quarter valued at about $2,183,619,000. JPMorgan Chase & Co. bought a new stake in shares of Cencora during the first quarter valued at approximately $1,199,695,000. Boston Partners purchased a new stake in shares of Cencora in the first quarter valued at approximately $1,001,269,000. Capital Research Global Investors bought a new position in Cencora in the first quarter worth approximately $650,424,000. Finally, Bessemer Group Inc. purchased a new position in Cencora during the 1st quarter worth $556,245,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Bank of America restated a “neutral” rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Robert W. Baird dropped their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Finally, StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $259.44.

Cencora Stock Up 4.9 %

Shares of COR stock opened at $245.38 on Thursday. The stock’s fifty day moving average price is $231.57 and its 200 day moving average price is $230.64. Cencora, Inc. has a 1-year low of $191.11 and a 1-year high of $247.66. The company has a market cap of $48.35 billion, a price-to-earnings ratio of 26.64, a price-to-earnings-growth ratio of 1.49 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares in the company, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.